Research showcasing the benefits of BioTissue AmnioGraft and Prokera were presented at the recent ASCRS 2023 conference in San Diego. Among those advancements were papers and posters summarizing several investigator-initiated studies examining the efficacy of the BioTissue AmnioGraft® amniotic membrane surgical eye graft and Prokera® biologic corneal bandages.
“Physicians continue to realize the benefits of cryopreserved amniotic membrane to elevate the standard of care. BioTissue technology can help improve patient outcomes and save valuable time in the operating room,” said Scheffer C.G. Tseng, M.D., Ph.D., Founder and Chief Technology Officer, BioTissue. “It is exciting to see the multiple applications and advantages of our innovative products showcased in a range of research being presented at ASCRS.”
IMPROVED OUTCOMES & EFFICIENCY FOR PTERYGIUM SURGERY
Traditionally, pterygium surgery can be challenging, time-consuming, and often produces less-than-optimal results for the patient—including high rates of recurrence.
Neel R. Desai, M.D., who is among the nation’s foremost experts in ocular surface disease, conducted research examining outcomes of pterygium excision surgery using the TissueTuck sutureless technique with BioTissue AmnioGraft cryopreserved amniotic membrane. Findings suggest a low risk of recurrence and complications in cases of recurrent pterygium. Dr. Desai presented his paper, Outcomes of the TissueTuck Surgical Technique for Recurrent Pterygium, on Saturday, May 6.
Dr. Desai’s Cryopreserved Amniotic Membrane during Pterygium Excision: Health Economic Opportunity Analysis poster compares the average surgical duration and cost of pterygium surgery using the TissueTuck technique with pterygium surgery using conjunctival autograft. An additional paper on the topic, Retrospective Review of Pterygium Surgery with Cryopreserved Amniotic Membrane, was presented by Jose Quiceno, M.D., on Saturday, May 6.
OCULAR SURFACE OPTIMIZATION & RECONSTRUCTION
Outcomes after cataract surgery can be compromised by dry eye disease. In Ocular Surface Optimization with Cryopreserved Amniotic Membrane Prior to Cataract Surgery, Jeff Wongs, M.D., explored whether BioTissue Prokera biologic corneal bandages can sufficiently stabilize the ocular surface to improve accuracy of intraocular lens calculations and ultimately, post-operative outcomes for patients with moderate to severe dry eye disease.
BioTissue AmnioGraft cryopreserved amniotic membrane is also the focus of a study assessing the outcomes of ocular surface reconstruction surgery using the product in patients with conjunctivochalasis (CCh). Findings of Retrospective Review of Conjunctivochalasis Surgery with Cryopreserved Amniotic Membrane conclude that surgical treatment of CCh using the reservoir restoration procedure with AmnioGraft is safe and helps to restore tear film dynamics. This reduction in CCh severity was also accompanied with improvement in patient symptoms and corneal staining. A poster was prepared by principal investigator Jose Quiceno, M.D., for the conference.
For more information about ASCRS 2023, including a full schedule of paper and poster presentations, visit annualmeeting.ascrs.org.
Read the full press release from BioTissue.